ConvaTec Group Plc
CNVVF
Other OTC2.82
USD
+0.09
- -
ConvaTec Group Plc
CNVVF
(Other OTC)
Recent
price
2.82
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ConvaTec Group Plc is a medical products and technologies company specializing in advanced wound care, ostomy care, continence care, and infusion care. The company develops, manufactures, and markets advanced wound dressings and skin care products for the management of acute and chronic wounds, including diabetic foot ulcers and pressure injuries; ostomy devices, accessories, and personalized services for individuals with a stoma; continence products such as catheters for urinary issues; and disposable infusion sets used in insulin pump therapy and other continuous infusion treatments for conditions like diabetes and Parkinson’s disease. ConvaTec operates globally with a strong presence in North America, Europe, and more than 100 countries worldwide. Founded in 1978, it is headquartered in London, United Kingdom. Recent strategic developments include a strong focus on innovation with a robust new product pipeline, highlighted by the upcoming launch of Aquacel™ ConvaFiber™, a next-generation dressing building on its Hydrofiber® technology, expected in 2026. The company is also advancing its innovative nitric oxide-generating dressing, ConvaNiox™, aimed at transforming hard-to-heal wound management and currently under regulatory approval processes in the EU, UK, Australia, and the US. Its 2024 performance reflects a successful pivot to sustainable and profitable growth with broad-based revenue increases across chronic care categories, driven by products such as Aquacel Ag+ Extra™, InnovaMatrix®, and ConvaFoam™. Convatec also expanded partnerships in infusion care, collaborating with notable industry players including AbbVie, Beta Bionics, Ypsomed, Medtronic, and Tandem to broaden applications in diabetes and Parkinson’s therapies. Additionally, Convatec announced a $300 million share buyback program to return surplus capital to shareholders, reinforcing its financial strength and shareholder value commitment. The company’s key subsidiaries include Unomedical A/S, 180 Medical, and Convatec Inc., which support its global operations and product delivery. Convatec’s ongoing strategic focus aims for 5-7% annual organic revenue growth, operating margin expansion to the mid-20% range by 2026-2027, and double-digit adjusted EPS growth, supported by innovation and productivity enhancements. It targets markets with chronic conditions that require ongoing care, positioning itself as a leader in chronic wound management, ostomy care, continence care, and infusion therapy solutions. ConvaTec is publicly traded on the London Stock Exchange under ticker CNVVF and remains a constituent of the FTSE 100 Index. The company’s research and development emphasize patient-centric technologies, seeking at least 30% of sales from products less than five years old by 2025, establishing a competitive advantage through continuous product innovation in its core therapy areas. Overall, ConvaTec Group Plc is a leading global medical technology company focusing on long-term management of chronic health conditions with a diverse product portfolio and significant recent advancements in innovative wound and infusion care technologies. Its headquarters are located at 7th Floor, 20 Eastbourne Terrace, London, UK.